On the hypothesis that anti-TNF therapy may preserve the function of pancreatic beta cells, etanercept was introduced into the treatment regimen of a 48 year old man at a distance of four months from the diagnosis of LADA allowing to keep a low insulin dose and good metabolic control during his eleven years of disease [24]. The gene discussed is INS; the disease is latent autoimmune diabetes in adults.